Key result
Patients with primary cardiac lymphoma treated with systemic chemotherapy and post-chemotherapeutic radiation therapy had a longer median progression-free survival compared to those treated with chemotherapy alone.
Why the study?
Does systemic chemotherapy (R-CHOP) combined with radiation therapy provide long-term disease-free survival in a patient with primary cardiac lymphoma?
Case Report (n=13)
Does systemic chemotherapy (R-CHOP) combined with radiation therapy provide long-term disease-free survival in a patient with primary cardiac lymphoma?
While R-CHOP chemotherapy and radiation therapy can achieve long-term disease-free survival in primary cardiac lymphoma, clinicians must remain vigilant for delayed, severe radiation-induced cardiac complications.
Answers are grounded in this paper and cite their sources.
Suggests potential benefit of adding radiation after chemotherapy in primary cardiac lymphoma; leaves open validation in prospective trials with attention to late cardiac toxicity.
Primary cardiac lymphoma (PCL) is a rare disease entity with only a few reported cases in Korea. In this paper, we report a case of PCL in a 59-year-old man presenting with chest pain. Diffuse large B-cell lymphoma was diagnosed through a cardiac catheterization-assisted percutaneous endomyocardial biopsy, and there was no evidence of extracardiac involvement of the lymphoma.The patient had a complete clinical response after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radiation therapy. The patient experienced a long-term disease-free survival of over 4 years. However, he received coronary artery bypass graft surgery due to an acute myocardial infarction that occurred 3 years after the completion of the radiation therapy. Although the addition of radiation therapy to the treatment is thought to decrease the risk of relapse in patients with PCL, a careful and thorough consideration of the potential complications of radiation therapy, particularly with respect to cardiac complications, should be considered.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2010) conducted a case report in Primary cardiac lymphoma (n=13). Systemic chemotherapy and post-chemotherapeutic radiation therapy vs. Systemic chemotherapy alone was evaluated on Median progression-free survival (months). Patients with primary cardiac lymphoma treated with systemic chemotherapy and post-chemotherapeutic radiation therapy had a longer median progression-free survival compared to those treated with chemotherapy alone.
Synapse has enriched 10 related papers. Consider them for comparative context: